Medicine and Dentistry
Cytoreductive Surgery
100%
Hyperthermic Intraperitoneal Chemotherapy
99%
Surgery
52%
Neoplasm
41%
Carcinomatous Peritonitis
32%
Gallbladder Cancer
29%
Overall Survival
28%
Peritoneum Metastasis
27%
Colorectal Liver Metastasis
27%
Peritoneum Cancer
24%
Adenocarcinoma
20%
Pancreaticoduodenectomy
18%
Patient Selection
18%
Transversus Abdominis Plane Block
18%
Opiate
18%
Recurrent Disease
18%
Cancer
16%
Adjuvant Therapy
12%
Multivariate Analysis
11%
Neoadjuvant Chemotherapy
11%
Hepatectomy
10%
Primary Tumor
10%
Diseases
10%
Cholecystectomy
10%
Distal Pancreatectomy
9%
Treatment Effect
9%
Hepatocellular Carcinoma
9%
Proton-Pump Inhibitor
9%
Lower Anterior Resection
9%
Midgut volvulus
9%
Surgical Oncology
9%
Learning Curve
9%
Splenic Flexure
9%
Lymph Node
9%
Hepatobiliary Cancer
9%
Adjuvant Chemotherapy
9%
Pancreas Cancer
9%
Squamous Cell Carcinoma
9%
Health Care Cost
9%
Sigmoid
9%
Stomach Paresis
9%
Biological Marker
9%
Pancreas Adenocarcinoma
9%
Retroperitoneal Lymph Node Dissection
9%
Lymphocyte
9%
Liver Tumor
9%
Ultrasonography
9%
Diaphragm
8%
Intensive Care Unit
8%
Infusion Fluid
7%
Keyphrases
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
100%
Cytoreductive Surgery
89%
Gallbladder Cancer
36%
Peritoneal Carcinomatosis
31%
Peritoneal Metastasis
27%
Colorectal Liver Metastases
27%
Peritoneal Cancer Index
23%
Overall Survival
21%
Patient Selection
21%
Low-grade Appendiceal mucinous Neoplasm
20%
Tumor
19%
Postoperative Outcomes
18%
Pancreaticoduodenectomy
18%
Ablating
18%
Transversus Abdominis Plane Block
18%
Embolize
18%
Opiate Use
18%
Resection
16%
Pancreatic Resection
14%
Adjuvant Therapy
13%
High-volume Center
12%
Minimally Invasive
12%
Oncological Outcomes
12%
Pathologic
12%
Multivariate Analysis
11%
Adenocarcinoma
11%
Single Institution
11%
Gallbladder
10%
Neoadjuvant Chemotherapy
10%
Appendiceal
10%
Opiate Consumption
10%
Primary Tumor
10%
Surgical Management
10%
Whirlpool
9%
Postoperative Day
9%
Liver Ultrasound
9%
Partial Response
9%
Total Lymph Node Count
9%
Treatment Effect
9%
Learning Curve
9%
Adenocarcinoma Subtype
9%
Pancreatic Cancer
9%
Response to Neoadjuvant Chemotherapy
9%
Area Deprivation
9%
Area Deprivation Index
9%
Surgical Oncology
9%
Normal Anatomy
9%
Duodenum
9%
Molecular Biomarkers
9%
Splenic Flexure Mobilization
9%